Literature DB >> 4742843

The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosis.

D C Dale, A S Fauci, S M Wolff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4742843     DOI： 10.1002/art.1780160510

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  10 in total

Review 1.  The current status of neutrophil cytoplasmic antibodies.

Authors:  F J van der Woude; M R Daha; L A van Es
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies.

Authors:  M T Keogan; V L Esnault; A J Green; C M Lockwood; D L Brown
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 3.  Clinical use of immunosuppressive drugs: part I.

Authors:  N L Gerber; A D Steinberg
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Quantitative and qualitative effects of cyclophosphamide administration on circulating polymorphonuclear leucocytes.

Authors:  G W Hunninghake; A S Fauci
Journal:  Immunology       Date:  1976-07       Impact factor: 7.397

5.  Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.

Authors:  R J ten Berge; H K van Walbeek; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1982-12       Impact factor: 4.330

6.  Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissues.

Authors:  M G Braun; E Csernok; W L Gross; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

7.  Mesna side effects which imitate vasculitis.

Authors:  E Reinhold-Keller; J Mohr; E Christophers; K Nordmann; W L Gross
Journal:  Clin Investig       Date:  1992-08

8.  Positron emission tomography scanning in anti-neutrophil cytoplasmic antibodies-associated vasculitis.

Authors:  Michael J Kemna; Frédéric Vandergheynst; Stefan Vöö; Didier Blocklet; Thomas Nguyen; Sjoerd A M E G Timmermans; Pieter van Paassen; Elie Cogan; Marinus J P G van Kroonenburgh; Jan Willem Cohen Tervaert
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

9.  Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.

Authors:  Victoria L Wolf; Erin B Taylor; Michael J Ryan
Journal:  Physiol Rep       Date:  2019-05

10.  The Synergistic Effects of Polysaccharides and Ginsenosides From American Ginseng (Panax quinquefolius L.) Ameliorating Cyclophosphamide-Induced Intestinal Immune Disorders and Gut Barrier Dysfunctions Based on Microbiome-Metabolomics Analysis.

Authors:  Rongrong Zhou; Dan He; Jing Xie; Qingyijun Zhou; Hongliang Zeng; Hongmei Li; Luqi Huang
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.